VRTX
Vertex Pharmaceuticals Incorporated454.96
-0.75-0.17%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Povi safety, payers reassured
Q&A centered on povitacept, reassuring investors on hypogammaglobulinemia risks with RUBY-3 data showing no SAEs or infections despite IgG dips averaging normal levels. Management detailed 74 payer engagements covering 210 million lives progressing well, DSMB's clean bill for RAINIER Ph3, and a 56% proteinuria reduction proxy from Ph2. Europe Alevtrex benefits from lighter monitoring and naive uptake; Gernavix shifts retail-ward. Payers are listening closely. Answers reaffirmed pipeline momentum without walk-backs, with eyes on renal readouts.
Key Stats
Market Cap
116.65BP/E (TTM)
32.06Basic EPS (TTM)
14.19Dividend Yield
0%Recent Filings
10-K
FY2025 results
Vertex drove FY2025 revenues to $12.0B, up 9% y/y, with TRIKAFTA/KAFTRIO at $10.3B (up 1%) powering the gain while ALYFTREK added $838M in its launch year; Q4 saw CASGEVY hit 30 infusions (64 total) and JOURNAVX exceed 550K prescriptions since March. CF margins held steady at 13.8% cost of sales despite mix shift, yet R&D/SG&A climbed 13% to $5.7B fueling pipeline momentum—povetacicept BLA rolling in Q4, inaxaplin interim due late 2026. Cash swelled to $12.3B; $619M buybacks executed. Q4 accelerated non-CF ramps. Pipeline delays threaten quarterly momentum.
8-K
Vertex revenue up 9%, guides higher
10-Q
Q3 FY2025 results
Vertex posted Q3 revenues of $3.1B, up 11% y/y from $2.8B, driven by TRIKAFTA/KAFTRIO's 3% gain to $2.7B and ALYFTREK's $247M launch ramp. Gross margin held steady at 86.5% despite mix shift. Operating income rose 6% y/y to $1.2B; diluted EPS climbed to $4.20 from $4.01 on 257.6M shares. Cash hit $12.0B after $3.1B operating cash flow, funding $1.9B buybacks; $500M revolver sits undrawn. Q1 $379M VX-264 impairment hit YTD intangibles. Royalty Pharma arbitration over ALYFTREK royalties brews.
8-K
Q3 revenue up 11%
Vertex posted Q3 revenue of $3.08B, up 11% from 2024, fueled by CF strength and early CASGEVY, JOURNAVX ramps. Refined FY25 guidance narrows revenue to $11.9-$12.0B while lifting non-GAAP R&D/AIPR&D/SG&A to $5.0-$5.1B for povetacicept acceleration, JOURNAVX push. Pipeline advances: povetacicept IgAN Phase 3 fully enrolled. Cash pile hits $12.0B.
10-Q
Q2 FY2025 results
Vertex Pharmaceuticals posted solid Q2 FY2025 results, with net product revenues climbing 11% year-over-year to $2.9 billion, fueled by 4% growth in TRIKAFTA/KAFTRIO to $2.6 billion and initial sales from ALYFTREK, CASGEVY, and JOURNAVX launches. Gross margin held steady at 86%, while operating income surged to $1.2 billion from a $3.5 billion loss last year, thanks to the absence of the $4.4 billion Alpine acquisition charge; diluted EPS rose to $3.99 from a $13.92 loss. Cash from operations hit $1.9 billion year-to-date, bolstering the $12.0 billion liquidity position with no debt drawn on the $500 million revolver. Early pipeline momentum shines in CF and autoimmune programs. Yet competition in gene therapies looms large.
ATXS
Astria Therapeutics, Inc.
12.87-0.05
BMRN
BioMarin Pharmaceutical Inc.
51.77-0.35
KALV
KalVista Pharmaceuticals, Inc.
15.90-1.00
KYTX
Kyverna Therapeutics, Inc.
10.24-0.58
LXRX
Lexicon Pharmaceuticals, Inc.
1.20-0.03
SION
Sionna Therapeutics, Inc.
42.89+0.13
TRDA
Entrada Therapeutics, Inc.
11.37+0.34
VERA
Vera Therapeutics, Inc.
48.30-0.91
VRNA
Verona Pharma plc
106.91+0.00
XRTX
XORTX Therapeutics Inc.
0.59-0.01